Health
KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
WHIPPANY, N.J., March 16, 2026--The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from ba
About this update from Bayer Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"KERENDIA® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline to Month 32 – a surrogate endpoint for slowing kidney disease progression1","length":259,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"FIND-CKD is the fifth consecutive Phase III clinical trial where KERENDIA met its primary endpoint, adding to a clinical trial program of more than 20,000 patients across multiple patient populations with heart and kidney diseases","length":230,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"FIND-CKD is the largest Phase III study to date focused on non-diabetic chronic kidney disease (CKD) and now expands KERENDIA’s clinical data in CKD to both diabetic and non-diabetic patients","length":191,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The clinical data from FIND-CKD will be presented at an upcoming scientific conference, and Bayer anticipates submitting the data to the U.S. Food and Drug Administration (FDA) to extend the indication of KERENDIA to this patient population","length":240,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"KERENDIA is currently approved by the FDA for use in adults with CKD associated with type 2 diabetes (T2D) and heart failure with left ventricular ejection fraction (HF LVEF) ≥40%2","length":180,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1100,"olType":false},{"type":"text","content":"WHIPPANY, N.J., March 16, 2026--(BUSINESS WIRE)--The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from baseline to Month 32,1 a validated surrogate endpoint for kidney disease progression.3 The safety profile of KERENDIA in the FIND-CKD study was consistent with its established safety profile.1","length":707,"tagName":"p"},{"type":"text","content":"The FIND-CKD clinical ...